Total Payments
$2.6M
2024 Payments
$461,183
Companies
44
Transactions
1,714
Payment Breakdown by Category
Other$1.2M (47.5%)
Consulting$833,501 (31.7%)
Travel$470,024 (17.9%)
Research$42,527 (1.6%)
Food & Beverage$34,582 (1.3%)
Education$1,006 (0.0%)
Gifts$11.97 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 423 | 44.8% |
| Consulting Fee | $833,501 | 215 | 31.7% |
| Travel and Lodging | $470,024 | 617 | 17.9% |
| Honoraria | $68,130 | 21 | 2.6% |
| Unspecified | $42,527 | 40 | 1.6% |
| Food and Beverage | $34,582 | 379 | 1.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,213 | 1 | 0.0% |
| Education | $1,006 | 14 | 0.0% |
| Gift | $11.97 | 4 | 0.0% |
Payments by Type
General
$2.6M
1,674 transactions
Research
$42,527
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $565,136 | 322 | $0 (2024) |
| HEMA Biologics, LLC | $239,828 | 279 | $0 (2024) |
| CSL Behring | $229,940 | 171 | $0 (2024) |
| Genentech USA, Inc. | $216,554 | 164 | $0 (2024) |
| Novo Nordisk Health Care AG | $206,377 | 77 | $0 (2024) |
| F. Hoffmann-La Roche AG | $169,333 | 109 | $0 (2024) |
| Novo Nordisk Inc | $168,962 | 102 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $159,760 | 112 | $0 (2024) |
| Spark Therapeutics, Inc. | $94,618 | 59 | $0 (2024) |
| Shire North American Group Inc | $85,460 | 56 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $461,183 | 283 | GENZYME CORPORATION ($180,072) |
| 2023 | $592,448 | 421 | GENZYME CORPORATION ($191,118) |
| 2022 | $348,125 | 279 | GENZYME CORPORATION ($123,274) |
| 2021 | $194,527 | 132 | GENZYME CORPORATION ($32,398) |
| 2020 | $152,688 | 85 | GENZYME CORPORATION ($38,274) |
| 2019 | $279,534 | 163 | F. Hoffmann-La Roche AG ($69,351) |
| 2018 | $355,349 | 183 | Genentech USA, Inc. ($90,495) |
| 2017 | $245,750 | 168 | Shire North American Group Inc ($43,693) |
All Payment Transactions
1,714 individual payment records from CMS Open Payments — Page 1 of 69
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $4,144.63 | Research |
| Study: An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors • Category: Hematology | ||||||
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $1,970.25 | Research |
| Study: An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors • Category: Hematology | ||||||
| 12/12/2024 | CSL Behring | HEMGENIX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,920.00 | General |
| Category: Hematology | ||||||
| 12/12/2024 | Novo Nordisk Health Care AG | Novoeight (Drug) | Consulting Fee | Cash or cash equivalent | $980.00 | General |
| Category: Hemophilia | ||||||
| 12/12/2024 | PFIZER INC. | BENEFIX (Biological), BEQVEZ, HYMPAVZI | Food and Beverage | In-kind items and services | $32.20 | General |
| Category: HEMATOLOGY | ||||||
| 12/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 12/06/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 12/06/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $128.91 | General |
| 11/25/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| 11/22/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,384.00 | General |
| Category: Hematology | ||||||
| 11/21/2024 | GENZYME CORPORATION | ALPROLIX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,384.00 | General |
| Category: Hematology | ||||||
| 11/21/2024 | CSL Behring | HEMGENIX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,460.00 | General |
| Category: Hematology | ||||||
| 11/21/2024 | GENZYME CORPORATION | ALPROLIX (Biological) | Travel and Lodging | Cash or cash equivalent | $167.99 | General |
| Category: Hematology | ||||||
| 11/21/2024 | GENZYME CORPORATION | ALPROLIX (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Hematology | ||||||
| 11/21/2024 | CSL Behring | HEMGENIX (Biological) | Travel and Lodging | Cash or cash equivalent | $40.88 | General |
| Category: Hematology | ||||||
| 11/21/2024 | GENZYME CORPORATION | ALPROLIX (Biological) | Travel and Lodging | Cash or cash equivalent | $38.67 | General |
| Category: Hematology | ||||||
| 11/20/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,400.00 | General |
| Category: Hematology | ||||||
| 11/20/2024 | GENZYME CORPORATION | ALPROLIX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,384.00 | General |
| Category: Hematology | ||||||
| 11/20/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | In-kind items and services | $1,770.75 | General |
| Category: Hematology | ||||||
| 11/20/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,692.00 | General |
| Category: Hematology | ||||||
| 11/20/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | In-kind items and services | $1,492.33 | General |
| Category: Hematology | ||||||
| 11/20/2024 | GENZYME CORPORATION | ALPROLIX (Biological) | Travel and Lodging | In-kind items and services | $145.02 | General |
| Category: Hematology | ||||||
| 11/20/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS. | F. Hoffmann-La Roche AG | $9,448 | 2 |
| An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | F. Hoffmann-La Roche AG | $6,563 | 4 |
| ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | GENZYME CORPORATION | $5,000 | 11 |
| Emicizumab is well-tolerated and effective in people with congenital hemophilia A regardless of age severity of disease or inhibitor status: a scoping review | F. Hoffmann-La Roche AG | $4,318 | 1 |
| A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS | F. Hoffmann-La Roche AG | $3,738 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRI | F. Hoffmann-La Roche AG | $3,359 | 2 |
| Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors, Phase 3 emicizumab Q4W in patients with hemophilia A, Phase III Inhibitor Study and Open Label Phase III Study of emicizumab in Hemophilia A Pediatrics Patients with Inhibitors | F. Hoffmann-La Roche AG | $3,163 | 4 |
| ATLAS-PPX: an Open-label, Multinational, Switching Study to Describe the Efficacy and Safety of Fitusiran Prophylaxis in Patients With Hemophilia A and B Previously Receiving Factor or Bypassing Agent Prophylaxis. | GENZYME CORPORATION | $2,750 | 5 |
| Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in previously treated children, adolescents, and adults with severe hemophilia A: Final results from ASPIRE | BIOVERATIV THERAPEUTICS INC. | $972.38 | 3 |
| Long-term efficacy and safety of prophylactic treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe haemophilia A: final longitudinal analysis of A LONG/Kids A-LO | BIOVERATIV THERAPEUTICS INC. | $893.33 | 1 |
| Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study | F. Hoffmann-La Roche AG | $700.87 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL | F. Hoffmann-La Roche AG | $683.27 | 2 |
| Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE) | BIOVERATIV THERAPEUTICS INC. | $523.60 | 1 |
| EMICIZUMAB FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A: INTERIM ANALYSIS OF HAVEN 7 | F. Hoffmann-La Roche AG | $247.36 | 1 |
| A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment | BIOVERATIV THERAPEUTICS INC. | $166.51 | 1 |
About Dr. Guy Young, M.D
Dr. Guy Young, M.D is a Pediatric Hematology-Oncology healthcare provider based in Bozeman, Montana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629175195.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Guy Young, M.D has received a total of $2.6M in payments from pharmaceutical and medical device companies, with $461,183 received in 2024. These payments were reported across 1,714 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Other Specialties Pediatric Hematology-Oncology
- Location Bozeman, MT
- Active Since 09/19/2006
- Last Updated 04/10/2025
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1629175195
Products in Payments
- SevenFact (Biological) $238,997
- HEMGENIX (Biological) $204,137
- HEMLIBRA (Biological) $191,083
- ALTUVIIIO (Biological) $184,052
- ALPROLIX (Biological) $92,208
- NovoSeven RT (Drug) $82,208
- Non-Covered Product (Drug) $67,220
- Alphanate (Biological) $61,862
- NUWIQ (Biological) $57,528
- ELOCTATE (Biological) $55,342
- Hemlibra (Biological) $52,068
- ROCTAVIAN (Drug) $34,692
- ADVATE (Biological) $31,276
- ADYNOVATE (Biological) $23,750
- ALPROLIX (Drug) $23,569
- FEIBA (Biological) $22,322
- Rebinyn (Biological) $20,187
- CEPROTIN (Biological) $19,677
- NO PRODUCT DISCUSSED (Drug) $17,899
- Novoeight (Drug) $17,673
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.